Pediatric antidepressant use after the black-box warning

Susan H. Busch, Colleen L. Barry

Research output: Contribution to journalArticlepeer-review

Abstract

In 2004 the Food and Drug Administration (FDA) required a black-box warning on antidepressants that describes a possible suicide risk in children. An analysis of the events, evidence, and FDA actions reveals information asymmetries that affect various players' ability to identify and act on risks. Antidepressant use declined sharply overall, not just among children, and the FDA's emphasis on the proven efficacy of fluoxetine (generic Prozac) did not prompt dramatic shifts in prescribing. We conclude that risk communication strategies need to be refined, to ensure intended results.

Original languageEnglish (US)
Pages (from-to)724-733
Number of pages10
JournalHealth Affairs
Volume28
Issue number3
DOIs
StatePublished - May 2009

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Pediatric antidepressant use after the black-box warning'. Together they form a unique fingerprint.

Cite this